Radiotherapy quality assurance: time for everyone to take it seriously.
Like high-risk industries, radiotherapy requires intense attention to detail, alertness, precision, and adequate human and material resources to minimise the risk of irreversible consequences. Clinical trials data such as that generated by the Quality Assurance programme of the Radiotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC) in this issue of the Journal have been instrumental in identifying problems with technical quality, the understanding of which can have a direct impact on improving the quality of care in the community. Consistency in absolute dosimetry, dose delivery, volume definition and reproducibility are paramount in radiotherapy quality assurance and have become even more important with the advent of conformal therapy. Extension of these principles to other oncological disciplines has added an additional dimension of improvement. Waiting times and measures of access must also be monitored if overall quality at the population level is to be assessed and enhanced. Lessons should be learned from clinical trials methodology in the use of intervention-specific guidelines, physician education and real time audit of treatment planning decisions. In the future, novel approaches, such as web based systems may further improve education and audit. Wider application and audit of evidence-based management guidelines about the use radiotherapy will bring to standard clinical practice the quality benefits that are considered a basic minimum standard for clinical trials.
National Cancer Institute of Canada Clinical Trials Group, Canada.
Peter
P
Dixon
Brian
B
O'Sullivan
D002986:Clinical Trials as Topic; D019583:Dose Fractionation, Radiation; D006297:Health Services Accessibility; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D017410:Practice Guidelines as Topic; D011785:Quality Assurance, Health Care; D011879:Radiotherapy Dosage; D012307:Risk Factors